GSK · GSK plc
AI read · Neutral
The AI's read
These ratings do not show that GSK's sales, medicines, or results have changed. One analyst lowered its view, and another raised theirs, so the story gives no clear reason to change GSK's outlook.
Analyst Rating Changes for GSK plc
Neutral
Jefferies cut GSK's rating and target, but AlphaValue/Baader Europe upgraded it to Buy. These opposite views report no change to GSK's business, so the story leaves its outlook unchanged.
Get alerts for GSK
Follow GSK plc (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSKFree on the App Store and Google Play, or on the web.